- Home
- LDWY vs CYCN Comparison
LDWY vs CYCN Comparison
Compare LDWY & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LDWY | CYCN |
|---|---|---|
| Founded | 1990 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 7.6M |
| IPO Year | 1991 | N/A |
Fundamental Metrics
Financial Performance| Metric | LDWY | CYCN |
|---|---|---|
| Price | $3.31 | $1.51 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 50.0K | 49.9K |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.70 | N/A |
| Revenue | ★ $69,769,000.00 | $2,855,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.70 | ★ N/A |
| Revenue Growth | 121.91 | ★ 1371.65 |
| 52 Week Low | $3.11 | $1.28 |
| 52 Week High | $6.19 | $6.25 |
Technical Indicators
Market Signals| Indicator | LDWY | CYCN |
|---|---|---|
| Relative Strength Index (RSI) | 38.65 | 41.67 |
| Support Level | $3.11 | $1.43 |
| Resistance Level | $3.99 | $1.77 |
| Average True Range (ATR) | 0.32 | 0.12 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 11.31 | 15.38 |
Price Performance
Historical ComparisonAbout LDWY Lendway Inc. (DE)
Lendway Inc is a specialty agricultural and finance company focused on making and managing its ag investments in the United States and internationally. The company operates in industries: Specialty Ag, consisting of the Bloomia business.
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.